Desire Max (PT-141) 10

Desire Max (Bremelanotide PT-141) and  marketed as Vyleesi is a synthetic peptide and melanocortin receptor agonist. Here are the key details: FDA Status: Approved by FDA in 2019 Marketed under brand name Vyleesi For premenopausal women with hypoactive sexual desire disorder (HSDD) Mechanism of Action: Activates melanocortin receptors (primarily MC4R) Affects the central nervous system Influences sexual behavior and desire Does not affect dopamine pathways like other similar medications Administration: Subcutaneous injection Typically administered 45 minutes before anticipated sexual activity Not to exceed one dose per 24 hours Not to exceed 8 doses per month Common Side Effects: Nausea Flushing Injection site reactions Headache Vomiting Important Considerations: Not for use in men Contraindicated in patients with uncontrolled hypertension Should not be used with alcohol Requires prescription and proper medical supervision Historical Development: Originally developed from Melanotan II Studied for various applications before HSDD approval Care information Store in a cool, dry place away from light. If Constituted, Please Refrigerate For long-term storage, freezing at -20°C is recommended to maintain integrity. WARNING : This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This  designation allows the use of research chemicals strictly for in vitro  testing and laboratory experimentation only. All product information  available on this website is for educational purposes only. Bodily  introduction of any kind into humans or animals is strictly forbidden by  law. This product should only be handled by licensed, qualified  professionals. This product is not a drug, food, or cosmetic and may not  be misbranded, misused or mislabeled as a drug, food or cosmetic